Prevalence and management of tuberculosis infection in Apulian rheumatologic patients treated with biologics: An observational cohort 10‐year study from the BIOPURE registry

• DOI: 10.1111/eci.13913
• Publication Date: 2022-11-27T20:09:49Z
• Authors: Marco Fornaro; Stefano Stano; Delia Goletti; Angelo Semeraro; Francesco Paolo C...; Nicola Maruotti; Sergio Colella; Anna Abbruzzese; Leonardo Santo; Emanuela Praino; Florenzo Iannone
• Keywords: Male; Adult; Biological Products; Tuberculin Test; bDMARD; screening; 610; Middle Aged; 3. Good health; Arthritis, Rheumatoid; 03 medical and health sciences; 0302 clinical medicine; tuberculosis; Latent Tuberculosis; Antirheumatic Agents; 616; Prevalence; Humans; Tuberculosis; Female; Interferon-gamma Release Tests; rheumatologic disease; Aged

The objective of this study was to assess the 10-year prevalence latent tuberculosis infection (LTBI) among Apulian patients with rheumatic diseases (RDs). Secondary endpoint record new cases active TB disease and LTBI treated biologic disease-modifying antirheumatic drugs (bDMARDs).We analysed results from included in BIOPURE registry 2009 2018, who underwent QuantiFERON-TB Gold In-tube (QFT-GIT) test as screening before bDMARDs treatment. Demographic clinical data were recorded at time first QFT-GIT test. Administration preventive therapy bDMARD treatments for positive All infections during follow-up.The final population 3028 (855 rheumatoid arthritis, 1001 psoriatic 833 spondyloarthritis, 130 connective tissue diseases, 33 systemic vasculitis 176 other inflammatory conditions), more frequently female (67.2%), a mean age 52 ± 18 years. Patients QFT-GIT-positive elderly people, predominantly male higher diabetes comorbidity. 10.8%. Of note, no reactivation completed Three thousand sixteen followed over (42.6 30 months), five (.2%) developed TB, which corresponds .47 per 1000 person-years.In observation, use seems be safe rheumatologic according current recommendations. Nevertheless, primary did occur treatment biologicals.